SYNthesis Med Chem

Executive Summary

SYNthesis Med Chem is a global contract research organization (CRO) based in Cambridge, UK, specializing in small molecule drug discovery services. As a member of the Viva Biotech group, it leverages a hybrid model combining Western medicinal chemistry design with cost-effective synthetic chemistry execution in China. The company focuses on emerging modalities such as PROTACs, molecular glues, and antibody-drug conjugates (ADCs), positioning itself at the forefront of next-generation therapeutics. With a strong emphasis on integrated drug discovery, from hit identification to lead optimization, SYNthesis offers customizable solutions to biotech and pharmaceutical clients worldwide. The CRO market for small molecules continues to expand, driven by increasing R&D outsourcing and demand for specialized technologies. SYNthesis is well-placed to capture growth given its differentiated capabilities and access to Viva's global network. However, as a private company with limited public disclosure, visibility into financials and specific milestones is constrained. Overall, SYNthesis represents a niche but promising player in the CRO space, with moderate near-term growth prospects.

Upcoming Catalysts (preview)

• Q3 2026Launch of Expanded PROTAC and Molecular Glue Service Line75% success
• Q4 2026Strategic Partnership with a Top-20 Pharmaceutical Company40% success
• Q2 2027Opening of New Research Facility in Cambridge80% success